论文部分内容阅读
阿糖胞苷是当今治疗急性髓性白血病（AML）较有效的药物之一。从1990年起，我们对19例AML的病）L经诱导、巩固获完全缓解后，给予大剂量阿糖胞苷（HDAra－C）为主的联合方案强化疗。结果：19例中11例处于缓解，1例治疗相关死亡，7例骨髓复发。11例患儿CR时间为9月一68月，平均40月。其中有4例CCR＞5年，经统计5年生存率达57．9％。5年持续完全缓解率（CCR）达52．6％，其疗效明显高于未开展HDAra－C前。HDAra－C毒副作用小、治疗相关死亡率低，值得进一步推广使用。
Cytarabine is one of the more effective drugs in the treatment of acute myeloid leukemia (AML) today. Since 1990, 19 cases of AML disease L induced by the consolidation of complete remission, given high-dose cytarabine (HDAra-C) -based combination of intensive chemotherapy. Results: Of the 19 patients, 11 were in remission, 1 were treatment-related deaths, and 7 were bone marrow relapses. 11 cases of children with CR time from September to 68 months, an average of 40 months. Among them, 4 cases had CCR> 5 years, and the 5-year survival rate reached 57.9%. The 5-year sustained complete response rate (CCR) of 52.6% was significantly higher than that before HDAra-C. HDAra-C toxic side effects, treatment-related mortality is low, it is worth further promotion and use.